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Abstract
Background: Pathological skin scars, caused by cesarean section, affected younger mothers esthetically and
psychosocially and to some extent frustrated obstetricians and dermatologists. Umbilical cord mesenchymal stem
cells (UC-MSCs), as a population of multipotent cells, are abundant in human tissues, providing several possibilities
for their effects on skin scar tissues. Herein, we performed a randomized, double-blind, placebo-controlled, three-
arm clinical trial, aiming to assess the efficacy and safety of UC-MSCs in the treatment of cesarean section skin scars
among primiparous singleton pregnant women.
Methods: Ninety primiparous singleton pregnant women undergoing elective cesarean section were randomly
allocated to receive placebo, low-dose (3 × 106 cells), or high-dose (6 × 106 cells) transdermal hydrogel UC-MSCs on
the surface of the skin incision. The primary outcome was cesarean section skin scars followed after the sixth
month, assessed by the Vancouver Scar Scale (VSS).
Results: All the participants completed their trial of the primary outcome according to the protocol. The mean score of
estimated total VSS was 5.52 in all participants at the sixth-month follow-up, with 6.43 in the placebo group, 5.18 in the
low-dose group, and 4.71 in the high-dose group, respectively. No significant difference was found between-group in
the mean scores for VSS at the sixth month. Additional prespecified secondary outcomes were not found with significant
differences among groups either. No obvious side effects or adverse effects were reported in any of the three arms.
Conclusion: This randomized clinical trial showed that UC-MSCs did not demonstrate the effects of improvement of
cesarean section skin scars.
Trial registration: ClinicalTrials.gov identifier, NCT02772289. Registered on 13 May 2016.
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Background
Cesarean delivery has been increasing worldwide over
recent years, especially in China [1, 2]. It has become the
most common surgical intervention in many countries
for pregnant women [3]. Due to its association with ad-
verse outcomes for mothers and babies [4], cesarean de-
livery has become a great concern globally. Meanwhile,
pathological skin scars after cesarean section were a big
problem esthetically and psychosocially among younger
mothers, and to some extent, frustrating obstetricians
and dermatologists.
Pathological skin scars, such as hypertrophic scar, keloids,
and atrophic, are aberrant fibro-metabolic diseases resulting
from severe burn injury, blunt force trauma, wound infec-
tion, or other surgical interventions [5]. They are character-
ized by the proliferation of fibroblasts, accumulation of
collagen, and infiltration of inflammatory cells [6, 7]. Epi-
demiology studies indicated that the pathological skin scars
were found in 33 to 91% in subjects who suffered from
burn injury and 39 to 68% in cases who received surgery
[8]. Moreover, numerous sufferers have different degrees of
psychosocial disturbance, varying from mild to severe [9].
Currently, therapeutic strategies, such as occlusive dress-
ings, compression therapy, surgical excision, topical or
intralesional corticosteroids, radiotherapy, lasers, cryother-
apy, and a combination with other adjuvant topical drugs,
are commonly used for alleviating the severity of skin scars
[5, 7, 10, 11]. However, most of the aforementioned therap-
ies are ineffective or with unsatisfactory effects, including
high recurrence rates, hypo- or hyper-pigmentation, tel-
angiectasia, blisters, dermal atrophy, inflammation, erosion,
superficial ulceration, crusting, erythema, edema, burning
sensation, and pain at injection site [7].
Stem cells, especially mesenchymal stem cells (MSCs),
representing a population of multipotent cells, are abun-
dant in human tissues. They have aroused immense inter-
ests for clinical applications because of their easy
availability and potential for recovering [12, 13]. Substantial
animal and clinical studies have shown that MSCs can in-
hibit pathological fibrosis in many organs, such as the heart,
lung, and kidney, and therefore can improve the prognosis
of many diseases, such as liver injury, spinal cord injury,
acute respiratory distress syndrome, blood disease, and crit-
ical limb ischemia [14–19]. These provided a possibility of
skin scar tissue repair affected by MSCs.
MSCs, owing to their multifunctional roles, can migrate
to the wound sites directionally. They formed a part of
microenvironment, improved wound healing, and inhib-
ited pathological skin scars [20]. Among them, UC-MSCs
are most easily accessible, with low immunogenicity, and
can be expanded in vitro [21]. UC-MSCs can be easily iso-
lated and collected from the umbilical cord by using an
accessible procedure [22]. Previous researches have shown
that MSCs can suppress proliferation and activation of
keloid fibroblasts and inhibit extracellular matrix synthesis
through a paracrine signaling mechanism [23, 24], and
thus may be a novel topical agent for pathological skin
scar treatment. Liu and his colleges [16] found that trans-
plantation of MSCs via the ear artery can inhibit the
hypertrophic scarring in a rabbit ear hypertrophic scar
model significantly, indicating that MSCs may have poten-
tial clinical applications in modulating the process of
wound healing. Similarly, another research in a rabbit
model has demonstrated that local injection of MSCs effi-
ciently prevented hypertrophic scar formation by regulat-
ing inflammation [15]. In a case report, researchers found
that hydrogel with MSCs can accelerate wound healing
and ameliorate the condition of the wound in a diabetic
patient within only 3 weeks [25]. Taken together, these
studies suggested that MSCs can regulate the process of
wound healing and prevent pathological skin scar
formation.
In our present work, we conducted a randomized,
double-blind, placebo-controlled clinical trial in order to
assess the efficacy and safety of umbilical cord mesen-
chymal stem cells (UC-MSCs) in the treatment of
cesarean section skin scars among primiparous singleton
pregnant women. The effectiveness of UC-MSCs on
treating cesarean section skin scars, to our knowledge,
has not been reported yet in the literature. Our hypoth-
esis was that UC-MSCs can improve the degree of scar
repairing and increase the satisfaction of patients.
Methods
Primiparous singleton pregnant women undergoing
elective cesarean section in the Affiliated Foshan Mater-
nity & Child Healthcare Hospital, Southern Medical
University, a tertiary university-affiliated hospital, were
screened for participation in this double-blind, three-
arm, randomized, controlled trial. The number of deliv-
eries in our hospital has stabilized at approximately 12,
000 per year [26]. This trial has been registered at the
ClinicalTrials.gov (registration number NCT02772289)
and approved by the Ethics Committee of the Affiliated
Foshan Maternity & Child Healthcare Hospital, South-
ern Medical University.
The trial protocol was designed by the trial executive
committee and further approved by the institutional re-
view board of the hospital. The trial protocol has been
published in an international peer-reviewed journal in
the field of clinical trials [27] and presented at an inter-
national conference on stem cell and regenerative medi-
cine [28]. The trial UC-MSCs (1 × 106 cells each pump)
and matching placebo were donated from the Health-
Biotech Pharmaceutical Company (Beijing, China). The
company was not involved in the trial design, data ana-
lysis, manuscript preparation, publication, or presenta-
tion of the trial.
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The UC-MSCs were isolated from the umbilical cord
of a healthy donor after informed consent by the method
described above [22, 25]. Briefly, the umbilical cord tis-
sue was washed with phosphate-buffered saline (PBS)
and then minced into 1–2 mm3 fragments. These tissue
pieces were then incubated with 0.075% collagenase
(Sigma, St Louis, MO, USA) for 30 min and then 0.125%
trypsin (Gibco, Grand Island, NY, USA) for 30 min with
gentle agitation at 37 °C. Fetal bovine serum (FBS)
(Hyclone, Logan, UT, USA) was added to neutralize the
excess trypsin. The digested mixture was then passed
through a 100-μm filter to obtain cell suspensions. The
cells were plated at a density of 1 × 106 cells/cm2 in non-
coated T-25 or T-75 cell culture flasks. Growth medium
consisted of Dulbecco’s modified Eagle’s medium with
low glucose (DMEM-LG; Gibco) and 5% fetal bovine
serum, supplemented with 10 ng/mL vascular endothe-
lial growth factor (VEGF; Sigma), 10 ng/mL epidermal
growth factor (EGF; Sigma), 100 U penicillin/strepto-
mycin (Sigma), and 2 mM L-glutamine (Gibco). Cell cul-
tures were maintained in a humidified atmosphere with
5% CO2 at 37 °C. After 3 days of culture, the medium
was replaced and non-adherent cells were removed. The
medium was then changed twice weekly thereafter until
60–80% confluence had been reached. The obtained ad-
herent cells were replated at a density of 1 × 104/cm2.
The UC-MSCs released from the cell banking were
cultured and expanded in the good manufacturing prac-
tice (GMP) laboratory to prepare final cell products.
They were checked to be sterile and free from human im-
munodeficiency virus, cytomegalovirus, syphilis, myco-
plasma, hepatitis B virus, hepatitis C virus, Epstein–Barr
virus, and endotoxins. The CD73, CD105, CD90, CD151,
CD166, Oct4, nestin, and Sox2 are highly expressed (>
95%), and CD45, CD34, CD31, CD11b, CD184, and HLA-
DR are negative. The final UC-MSCs were activated and
mixed with sodium alginate powder, resulting in a gelatin-
ous UC-MSC complex. The UC-MSCs can be stored for a
year in a − 80 °C refrigerator, and the post-transplantation
cell survival should be more than 80%.
From November 2016 to September 2018, pregnant
women were referred to the study team for screening.
The eligibility of enrollment was confirmed by investiga-
tors. Primiparous singleton pregnant women aged 21 to
35 years between the 37th and 42nd weeks of gestation
were eligible for enrollment if they were going to have a
programmed cesarean delivery. Pregnant women with a
gel allergy were excluded because of the difficulty to
complete the trial in women with the symptom. Women
who were planning to have any other cosmetic proced-
ure to the skin incision during the study period and who
had a history of smoking, wounds or local disease in the
treatment area, recent or current cancer history, any sys-
temic uncontrolled disease, or presented with a keloid
formation were excluded. Women unwilling to adhere to
the trial protocol were also excluded. The supplementary
appendix provided the trial inclusion and exclusion cri-
teria. Written informed consent was obtained from all
the included subjects.
Routine blood examinations for aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), uric acid
(UA), blood urea nitrogen (BUN), and tumor markers
(CA125, CA153, CA199, and CEA) were carried before
skin incision. Meanwhile, physical examinations, past
medical histories, and pigmentation and erythema
around the skin incision were subsequently measured
and recorded.
Eligible participants who signed informed consent
forms were then randomly assigned in a 1:1:1 ratio, by
means of a computer algorithm, to allocate placebo,
low-dose (3 × 106), or high-dose (6 × 106) groups. Trans-
dermal hydrogel was occupied immediately after skin in-
cision suturing. The participants received a total of six
hydrogels on the surface of the skin incision, once a day.
Participants in the placebo group received placebo
hydrogel for 6 days; those in the low-dose group will re-
ceive one dose of hydrogel with cells for three consecu-
tive days and then placebo hydrogel for the next three
consecutive days; those in the high-dose group will re-
ceive cells for 6 days.
The primary outcome of cesarean section skin scars was
assessed at 6 months after enrollment by using Vancouver
Scar Scale (VSS). Four parameters were used in the
evaluation of the severity of cesarean section skin scars: pig-
mentation (normal, hypopigmented, mixed, or hyperpig-
mented), vascularity (normal, pink, red, or purple), pliability
(normal, supple, yielding, firm, ropes, or contracture), and
height (flat, < 2mm, 2–5mm, or > 5mm) [29]. Each par-
ameter contained ranked subscales that may be summed to
obtain a total score ranging from 0 to 14, with 0 represent-
ing normal skin. The higher the total score, the more the
severity of the scarring. The outcome at the first and third
months after enrollment was also assessed.
Additional prespecified secondary outcomes included ad-
verse effects, wound healing at 14 days, erythema and pig-
mentation around the skin incision, skin scar area and
volume, immunoglobulins (IgG, IgA, IgM) and comple-
ment component (C3, C4) in milk, and satisfaction of treat-
ment (an overall assessment of the treatment, as measured
on a 5-point scale [with “very good,” “good,” “moderate,”
“slight,” or “none”] assessed by the questionnaire of “would
you recommend this method of treatment to a friend?”).
Statistical analysis
The sample size was calculated according to the primary
outcome of VSS. The score of VSS was evaluated ac-
cording to professor Yu-Chen Huang’s preliminary trial
in Taipei Medical University WanFang Hospital [30].
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The sample size of this anticipated trial was 74, and the
final sample size was increased to 90 (n = 30 in each
group) to achieve 90% power to detect 1.5 difference of
the VSS in the MSC group and the placebo group. Data
analysis was performed using R 3.1 software.
All the results were analyzed according to the
intention-to-treat principle. Standard descriptive
methods were used to summarize the trial participants
overall and by intervention group. Continuous variables
were demonstrated by mean ± standard deviation and
calculated by one-way analysis of variance (ANOVA).
Categorical variables were demonstrated by a relative
number and calculated by chi-square test. The primary
outcome was assessed among all women who had the
follow-up on the sixth month according to the
intention-to-treat principle. After homogeneity test of
characteristics of the participants at baseline among
groups, the difference (with 95% confidence interval) of
VSS of women between the MSC group and placebo
group was calculated using two-sided t test and F test.
After correcting of multiple comparisons by Bonferroni
correction, the differences were considered significant at
α = 0.017.
Subgroup analysis of the primary outcome according
to participants’ demographics and clinical characteristics
was prespecified. The analyses were stratified according
to gestational age and maternal age. Two-sided t test, F
test, chi-square test, or Fisher’s exact test was used to
compare the groups in all secondary analyses; the results
were presented without adjustment for multiplicity and
should be considered exploratory. All the data was ana-
lyzed by SPSS statistical software.
Results
From November 2016 to September 2018, a total of 16,
029 pregnant women gave birth in the department and
7796 (48.64%) women underwent cesarean delivery. In
these cesarean births, there were 5269 multipara women,
358 emergency cesarean sections, 677 too old (> 35 years)
or too young (< 21 years), 344 preterm delivery (before
gestational week 37), and 170 twin pregnancy. Of the 978
potential eligible participants, 486 pregnant women
planned to go to other cities after delivery, 25 pregnant
women were found with keloid formation, 36 women
were allergic to gelatin, and 341 women declined to par-
ticipate because of safety concerns. Finally, 90 eligible
singleton primiparous pregnant women were enrolled and
underwent randomization, with 30 women in each group
(Fig. 1). Participant recruitment closed when the sample
size reached ninety.
All the participants were occupied to the trial, and the
follow-ups of the primary outcome were finished accord-
ing to the protocol. The mean age and gestation were
28.04 years and 39.47 weeks, respectively. The mean time
of operation and the length of incision were 39.20 min
and 14.53 cm, respectively. The mean value of pigmenta-
tion and erythema was 165.37 and 265.43, respectively.
No abnormal liver and kidney indexes were found in all
participants. Women randomized to each of the three
groups were well balanced regarding demographic and
delivery characteristics (Table 1).
The mean total VSS score was 5.52 in all participants
at the sixth month, with 6.43 in the placebo group, 5.18
in the low-dose group, and 4.71 in the high-dose group,
respectively. No significant difference was found
between-group in the mean scores of VSS at the sixth
month. Similar results were also shown among groups at
the first and third months (Table 2 and Fig. 2). Repre-
sentative hematoxylin-eosin (H&E) staining pictures are
shown in Fig. 3.
For all additional prespecified secondary outcomes,
there were no significant differences among the three
groups. Detailed research data and statistical results
were provided in the attachment files. No obvious side
effects or adverse effects, such as fever, chills, pain, in-
flammation, and wound infection, were reported in any
of the three arms. Moreover, renal and liver functions
and tumor markers, including CA125, CA153, CA199,
and CEA, were all within the normal range (Table 3).
By the end of the trial period, 51.00% (46) of the
women described their experience overall as “slight” and
49.00% (44) described as “none.” None of them de-
scribed as “moderate,” “good,” or “very good.” However,
the majority of women (90% (81)) stated that they would
use the intervention again if there are any changes and
would recommend this treatment method to their
friends (Table 2).
Discussion
Based on the findings of the present work, UC-MSCs
did not demonstrate the effects of improvement of
cesarean section skin scars. No significant difference was
found between groups in terms of the VSS score, sec-
ondary and adverse-effect outcomes at the first-, third-,
and sixth-month follow-ups.
In a case-control prospective study by Abo-Elkheir
et al., the authors proved that MSCs can effectively en-
hance wound regeneration in deep burns, representing a
new modality providing great hope for burn injury pa-
tients [31]. A randomized phase 1/2 clinical trial focus-
ing on skin expansion showed that it was safe and
effective to intradermally transplant autologous stem
cells to promote mechanical stretch-induced skin regen-
eration in vivo and was a feasible clinical application to
provide amounts of tissue for complex skin defect [32].
Unfortunately, we could not observe significant cesarean
section skin scar improvement based on VSS rating and
other outcomes, such as wound healing at the second
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Fig. 1 Enrollment and outcomes
Table 1 Characteristics of the participants at baseline [mean ± SD or n (%)]
All participants Placebo group Low-dose group High-dose group F/χ2 p value
Age (years) 28.04 ± 3.39 28.01 ± 3.82 28.34 ± 3.05 27.79 ± 3.34 0.197 0.821
Age group
21–27 45 (50.0) 17 (56.7) 12 (40.0) 16 (53.3) 1.867 0.500
28–35 45 (50.0) 13 (43.3) 18 (60.0) 14 (46.7)
Gestation (week) 39.47 ± 1.10 39.50 ± 1.07 39.30 ± 1.25 39.61 ± 0.97 0.603 0.550
Gestation group
37–39 week 59 (65.6) 20 (66.7) 20 (66.7) 19 (63.3) 0.098 0.999
40–42 week 31 (34.4) 10 (33.3) 10 (33.3) 11 (36.7)
Operation time (min) 39.20 ± 10.45 39.17 ± 12.48 38.48 ± 7.87 39.93 ± 10.81 0.137 0.873
Incision length (cm) 14.53 ± 1.07 14.36 ± 1.23 14.73 ± 0.93 14.52 ± 1.05 0.881 0.418
Pigmentation 165.37 ± 73.15 167.99 ± 69.86 160.07 ± 81.14 168.13 ± 70.00 0.116 0.890
Erythema 265.43 ± 77.03 264.43 ± 77.75 271.99 ± 84.63 259.69 ± 69.93 0.188 0.829
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week, pigmentation and erythema around the incision,
and skin area and volume. We considered that the insuf-
ficient effective dose may be a key important cause.
Most of the previous effective clinical studies used the
doses of 108 or 109 cells [33, 34].
The number of cells, 106, seems inadequate in this
trial. What was more regrettable was that there were a
number of cells, about 10%, which performed inactively.
The reason that we focused on 106 UC-MSCs was the
full consideration of the safety for those sensitive popu-
lation, namely pregnant women. Although there was no
statistical difference, the present study found that the
VSS rating was lower with the dose increased. Under-
standing this appearance is of great significance for fu-
ture clinical trials that target higher doses of UC-MSCs
to intervene cesarean section skin scar.
The biological function of UC-MSC hydrogel was
complex, and the greater potential may be related to
Table 2 Vancouver Scar Scale and satisfaction outcomes among participants
All participants Placebo group Low-dose group High-dose group F/χ2 p value
VSS
First month 4.68 ± 1.49 5.17 ± 1.40 4.46 ± 1.53 4.46 ± 1.47 1.852 0.164
Third month 5.20 ± 1.74 5.48 ± 1.69 4.83 ± 1.63 5.40 ± 1.96 0.899 0.413
Sixth month 5.52 ± 2.70 6.43 ± 2.48 5.18 ± 2.79 4.71 ± 2.66 2.362 0.103
Satisfaction
Very good 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3.279 0.214
Good 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Moderate 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Slight 42 (46.7) 14 (46.7) 11 (36.7) 21 (70.0)
None 48 (53.3) 16 (53.3) 19 (63.3) 9 (30.0)
VSS Vancouver Scar Scale
Fig. 2 Mean difference of the Vancouver Scar Scale between the MSC and placebo group
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paracrine, immunomodulation, and the vascular differ-
entiation capacity of these cells. Several studies have
shown that MSCs can secrete multiple cytokines and
growth factors, including stromal cell-derived factor 1,
basic fibroblast growth factor (bFGF), TGF-β, IGF-1,
VEGF, and HGF, and increase angiogenesis and collagen
accumulation in the wound tissue [35–37]. It has been
reported that MSC hydrogel can stimulate wound tissue
to generate granulation tissues [25, 38]. Similarly, in this
study, the histologic evaluation showed that the capillary
density of skin scar was increased in UC-MSC groups.
In addition, in vivo evidence revealed that MSCs mark-
edly expressed the anti-inflammatory factor IL-10 and
suppressed the production of IL-6, IL-8, IL-1, IL-4,
TNF-α, interferon-γ, and ICAM-1 [35, 39, 40]. This indi-
cated that MSCs can induce high immunomodulation
activity and reduce inflammation during wound healing.
Another reason for negative findings may be due to in-
sufficient follow-up period. Some studies have suggested
that it usually took 18–24 months for a typical scar to
mature [11]. Considering a low rate of lost to follow-up
in the special group of pregnant women, we only
followed for 6 months at this design. Satisfactorily, all
the participants completed the trial, with a primary out-
come according to the protocol at the sixth month. In
the next step, we will further follow up to observe the
long-term efficacy in these participants.
Women with keloid formation may benefit from this
therapy. However, in order to control the confounding
deviation as much as possible, we excluded these women
in the trial. These women should be the focus of the
next study. In addition, our used stem cells were derived
from allogeneic cells supplied by the company manufac-
turing. If possible, trials using autologous stem cells may
yield better effectiveness.
A major concern with MSC therapy is the safety poten-
tial. In the present study, many eligible pregnant women
who declined to participate in the trial are concerned
about the short- and long-term safety of MSCs, especially
the concern regarding their future breastfeeding. To date,
Fig. 3 Representative hematoxylin-eosin (H&E) staining of cesarean section skin scars with the three groups. a Placebo group. b Low-dose group.
c High-dose group
Table 3 The value of the liver, kidney, and tumor markers before and at the sixth month [mean ± SD or median (Q25–Q75)]
Baseline Sixth month
All participants Placebo group Low-dose group High-dose
group
All participants Placebo group Low-dose
group
High-dose
group
ALT 9.72 ± 3.60 10.17 ± 4.04 9.63 ± 3.12 9.37 ± 3.65 16.82 ± 12.70 17.05 ± 9.97 17.09 ± 17.67 16.13 ± 6.54
AST 15.48 ± 3.40 15.93 ± 3.18 15.30 ± 3.04 15.20 ± 3.96 17.37 ± 6.34 16.62 ± 5.08 17.78 ± 7.94 17.75 ± 5.48
UA 345.58 ± 89.29 342.90 ± 83.96 328.40 ± 88.22 365.43 ± 94.42 333.10 ± 70.49 322.52 ± 62.01 343.48 ± 80.41 332.06 ± 67.91
BUN 3.77 ± 2.63 4.03 ± 4.42 3.61 ± 0.82 3.66 ± 0.93 4.65 ± 1.15 4.61 ± 1.01 4.74 ± 0.99 4.57 ± 1.55
CA125 19.63 (15.21–
26.75)
19.62 (15.19–
25.54)
19.36 (14.65–
30.49)
20.75 (15.36–
31.66)
15.13 (9.87–
19.72)
15.85 (9.65–
20.39)
13.18 (9.07–
18.53)
15.13 (9.45–
22.67)
CA153 13.21 (10.56–
16.07)
13.20 (10.70–
16.87)
12.81 (10.78–
16.32)
13.39 (9.68–
15.76)
8.62 (6.55–
12.30)
7.52 (6.27–
11.86)
8.89 (6.41–
12.44)
10.49 (7.33–
12.44)
CA199 9.54 (6.91–14.48) 9.29 (6.38–15.42) 8.66 (7.03–19.38) 10.27 (7.03–
14.47)
9.11 (6.48–
14.45)
10.58 (6.13–
15.45)
7.53 (6.53–
15.76)
10.78 (6.42–
14.13)
CEA 0.62 (0.31–0.87) 0.70 (0.30–0.85) 0.60 (0.38–0.90) 0.61 (0.21–0.83) 0.84 (0.53–1.48) 1.21 (0.54–1.59) 0.66 (0.51–1.39) 0.79 (0.60–1.38)
ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CA125 cancer antigen 125, CA153 carbohydrate antigen 153, CA199
carbohydrate antigen 199, CEA carcinoembryonic antigen, UA uric acid
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most of the published preclinical and clinical trials have
reported that MSCs are safe when being used for the
treatment of injuries to the central nervous system, biliary
lesions, musculoskeletal disease, digestive system disease,
and cardiovascular disease [17, 18, 33, 34, 41].
Meanwhile, a meta-analysis that included 36 articles,
involving a total of 1012 participants, evaluated the
safety of MSC-based therapy in all prospective clinical
trials [42]. This study did not detect any risk like malig-
nancy, infection, organ system complications, and acute
infusion toxicity in treated participants. On the other
hand, this study proved that intravascular infusions of
MSC therapy appeared to be safe. Our findings were
consistent with the evidence from the above studies that
the use of MSCs in pregnant women is safe.
Interestingly, although participants in both the placebo
and MSC groups were both not satisfied with the skin
scar at the sixth month, most of them still want to try it
again. It means that these younger mothers have grad-
ually accepted MSC therapy after this clinical trial and
looked forward to it.
Conclusions
In conclusion, in this three-arm RCT trial involving
women with primiparous singleton pregnancies, the UC-
MSC-treated group was not significantly different from
the placebo group for the reduction of cesarean section
skin scar and neither did the increasing recognition of
participants’ satisfaction.
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